In this video, health-care analyst David Williamson explains why this particular suspension shouldn't effect Merck too badly, but why investors should monitor the situation closely as public opinion could turn against these type of products.
Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.